{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Peter", "organization": "", "rank": 1, "lastname": "EAVIS"}], "original": "By PETER EAVIS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "The Upshot; compensation practices likely played role in downfall of Valeant Pharmaceuticals, drug giant that has seen shares fall some 90 percent following revelations about suspect accounting; chief executive J Michael Pearson had acquired shares amounting to 3 percent of company, largely through compensation, giving him strong incentive to see share price rise.  ", "multimedia": [{"type": "image", "url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbWide.jpg", "legacy": {"wide": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "The Upshot", "content_kicker": "Compensation", "print_headline": "Among Causes of Valeant\u2019s Tumble,  Outsize Executive Pay Shares Blame", "main": "Valeant Is a Reminder of the Peril of Outsize Executive Pay"}, "print_page": "3", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Pearson, John Michael (1959- )", "is_major": "Y", "rank": "2", "name": "persons"}, {"value": "Executive Compensation", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Income Inequality", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Boards of Directors", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Stock Options and Purchase Plans", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "8", "name": "subject"}], "snippet": "Compensation based largely on stock price performance probably played a role in the behavior that led to the drug company\u2019s rise and stunning fall.", "source": "The New York Times", "lead_paragraph": "Compensation based largely on stock price performance probably played a role in the behavior that led to the drug company\u2019s rise and stunning fall.", "word_count": "1122", "pub_date": "2016-04-05T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "The Upshot", "web_url": "http://www.nytimes.com/2016/04/05/upshot/valeant-is-a-reminder-of-the-peril-of-outsize-executive-pay.html", "_id": "57025f2838f0d81980921b09"}